The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose escalation study of weekly BI 836845, a fully human, affinity-optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid cancers.
Chia-Chi Lin
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Kwang-Yu Chang
No relevant relationships to disclose
Dennis C Huang
Employment or Leadership Position - Boehringer Ingelheim
Vicky Marriott
Employment or Leadership Position - Boehringer Ingelheim
Ludy Van Beijsterveldt
Employment or Leadership Position - Boehringer Ingelheim
Li-Tzong Chen
No relevant relationships to disclose
Ann-Lii Cheng
No relevant relationships to disclose